TransMedics Group (NASDAQ:TMDX) is transforming the standard of care in solid organ transplants in order to increase the number of organ transplants and improve clinical outcomes.
THIS WEEK'S FEATURE
MORE FEATURES
NEWS
Maxim doubles BioLineRx PT to $10 from $5
Maxim Group raised its price target for BioLineRx (NASDAQ:BLRX) to $10 from $5 on positive top-line data from the company’s Phase 3 GENESIS trial. The stock was quoted at $5.30, up $2.11, in afternoon trading on...
SVB Leerink starts VectivBio at OP; PT $28
SVB Leerink launched coverage of VectivBio Holding AG (NASDAQ:VECT) with an “outperform” rating and $28 price target. The stock closed at $15.21 on May 3. VectivBio is focused on developing treatments for severe rare...
WB cuts Lucira Heath to market perform
William Blair downgraded Lucira Health (NASDAQ:LHDX) to “market perform,” citing changes to the testing market that have played out over the last couple of months coupled with lack of demand for the company’s at-home...
Ripple Therapeutics appoints renowned ophthalmologist Dr. Jonathan Talamo to board
Closely-held Ripple Therapeutics named Jonathan Talamo, M.D., an internationally known ophthalmologist, innovator and consultant to the industry with more than 25 years of experience in healthcare, to the board. Dr...
Stifel starts ProQR Therapeutics at buy; PT $20
Stifel initiated coverage of ProQR Therapeutics N.V. (NASDAQ:PRQP) with a “buy” rating and price target of $20. The stock finished at $6.22 on April 30. “As a clinical-stage company with demonstrated proof-of-concept...
SVB Leerink cuts AVROBIO PT to $10 from $18
SVB Leerink reduced its price target for AVROBIO (NASDAQ:AVRO) to $10 from $18 but maintained its “market perform” rating after the company announced that it may no longer pursue an accelerated approval pathway for AVR...
Cantor starts Clene at OW; PT $22
Cantor Fitzgerald launched coverage of Clene (NASDAQ:CLNN) with an “overweight” rating and 12-month price target of $22. The stock closed at $9 on April 30. Clene is a neuro-innovator that is developing drugs to enhance...
BTIG starts DermTech at buy; PT $53
BTIG initiated coverage of DermTech (NASDAQ:DMTK) with a “buy” rating and $53 price target. The stock closed at $42.05 on April 30. DermTech provides genomic diagnostic testing for various skin diseases and conditions...
HCW starts Sio Gene Therapies at buy; PT $8
H.C. Wainwright initiated coverage of Sio Gene Therapies (NASDAQ:SIOX) with a “buy” rating and price target of $8. The stock closed at $2.70 on April 29. Sio is a gene therapy company with significant experience and...
Hepion Pharma presents machine learning “learn and confirm” modeling strategy at NASH Congress
Hepion Pharmaceuticals (NASDAQ:HEPA) SVP of clinical pharmacology and analytics, Dr. Patrick Mayo, gave a virtual presentation entitled, “CRV431 – From Benchtop to Bedside Clinical Development” at the 4th Global NASH...
Raymond James ups Cardiol Therapeutics to OP from MP
Raymond James upgraded Cardiol Therapeutics (TSX:CRDL) to “outperform” from “market perform,” citing enrollment of the first patient in a Phase 2/3 clinical trial investigating the cardioprotective properties of...
Three finalists named for 2021 Bloom Burton Award
Daniel Durocher, Ph.D., scientific co-founder of Repare Therapeutics; Carl Hansen, Ph.D., founder and CEO of AbCellera; and Hamed Shahbazi, chairman and CEO of WELL Health Technologies are the three finalists for the...
Just a few of the companies we’ve highlighted along the way
